Michael K. Gibson

13.6k total citations · 2 hit papers
155 papers, 6.5k citations indexed

About

Michael K. Gibson is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Michael K. Gibson has authored 155 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Pulmonary and Respiratory Medicine, 84 papers in Surgery and 66 papers in Oncology. Recurrent topics in Michael K. Gibson's work include Esophageal Cancer Research and Treatment (51 papers), Head and Neck Cancer Studies (48 papers) and Gastric Cancer Management and Outcomes (47 papers). Michael K. Gibson is often cited by papers focused on Esophageal Cancer Research and Treatment (51 papers), Head and Neck Cancer Studies (48 papers) and Gastric Cancer Management and Outcomes (47 papers). Michael K. Gibson collaborates with scholars based in United States, Japan and Greece. Michael K. Gibson's co-authors include James D. Luketich, Arjun Pennathur, Blair A. Jobe, Arlene A. Forastiere, Robert L. Ferris, Dwight E. Heron, C C Harris, Xin Wei Wang, Kenneth S. Korach and Athanassios Argiris and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Michael K. Gibson

144 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oesophageal carcinoma

2013 1.9k citations Michael K. Gibson, James D. Luketich et al. profile →
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

2017 497 citations Joshua Bauml, Tanguy Y. Seiwert et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael K. Gibson United States	33	2.8k	2.7k	2.6k	2.0k	1.3k	155	6.5k
Chao-Nan Qian China	41	758 0.3×	1.9k 0.7×	1.1k 0.4×	2.6k 1.3×	853 0.6×	101	5.2k
Isaiah W. Dimery United States	29	722 0.3×	2.2k 0.8×	1.3k 0.5×	1.7k 0.9×	903 0.7×	68	4.6k
Mona F. Melhem United States	30	588 0.2×	1.9k 0.7×	858 0.3×	2.0k 1.0×	490 0.4×	45	4.5k
Ling Guo China	33	798 0.3×	1.2k 0.5×	691 0.3×	1.3k 0.6×	1.2k 0.9×	168	3.4k
Mario Sarbia Germany	40	2.4k 0.9×	1.9k 0.7×	1.9k 0.7×	2.0k 1.0×	120 0.1×	151	6.1k
Keishi Yamashita Japan	44	1.9k 0.7×	2.2k 0.8×	2.0k 0.8×	3.4k 1.7×	90 0.1×	265	6.8k
Wenfeng Fang China	33	458 0.2×	3.4k 1.3×	2.4k 0.9×	1.1k 0.5×	277 0.2×	201	4.9k
Tomoya Yokota Japan	31	1.1k 0.4×	1.4k 0.5×	1.4k 0.5×	799 0.4×	400 0.3×	186	3.3k
Jianping Xiong China	36	772 0.3×	2.0k 0.7×	1.6k 0.6×	2.1k 1.1×	140 0.1×	189	5.0k
Christopher Stroh Germany	28	1.1k 0.4×	5.6k 2.1×	2.5k 0.9×	2.0k 1.0×	133 0.1×	78	8.0k

Countries citing papers authored by Michael K. Gibson

Since Specialization

Citations

This map shows the geographic impact of Michael K. Gibson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael K. Gibson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael K. Gibson more than expected).

Fields of papers citing papers by Michael K. Gibson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael K. Gibson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael K. Gibson. The network helps show where Michael K. Gibson may publish in the future.

Co-authorship network of co-authors of Michael K. Gibson

This figure shows the co-authorship network connecting the top 25 collaborators of Michael K. Gibson. A scholar is included among the top collaborators of Michael K. Gibson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael K. Gibson. Michael K. Gibson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cognetti, David M., Joseph Curry, Jennifer M. Johnson, et al.. (2025). Safety and Efficacy Findings From a Phase Ib/ II Study of ASP ‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Head & Neck. 48(1). 160–174.

Gibson, Michael K., et al.. (2024). Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ oropharyngeal cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS6118–TPS6118. 1 indexed citations

Eads, Jennifer R., Noah Graham, Michael K. Gibson, et al.. (2024). A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).. Journal of Clinical Oncology. 42(16_suppl). 4000–4000. 10 indexed citations

Lander, Eric, Vasily N. Aushev, Brandon M. Huffman, et al.. (2024). Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response. JCO Precision Oncology. 8(8). e2400288–e2400288. 1 indexed citations

Strickland, Matthew R., Eric Lander, Michael K. Gibson, et al.. (2024). Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management. Journal of the National Comprehensive Cancer Network. 22(3). 7 indexed citations

Colevas, A. Dimitrios, Christine H. Chung, Douglas R. Adkins, et al.. (2024). A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).. Journal of Clinical Oncology. 42(16_suppl). 6004–6004. 8 indexed citations

Thompson, Cheryl L., et al.. (2024). The distribution of esophageal cancer patients enrolled in care at the Uganda Cancer Institute by sub-regions, districts and ethnicity. African Health Sciences. 24(1). 198–205. 1 indexed citations

Lander, Eric, Brandon M. Huffman, Samuel J. Klempner, et al.. (2023). Circulating tumor DNA as a marker of recurrence risk in locoregional esophagogastric cancers with pathologic complete response.. Journal of Clinical Oncology. 41(4_suppl). 452–452. 3 indexed citations

Gibson, Michael K., et al.. (2023). Zolbetuximab: An Investigational First-Line Treatment for CLDN18.2-positive, HER2-negative Gastric and Gastro-oesophageal Junction Cancer. 19(2). 16–16. 1 indexed citations

10.

Dunn, Lara, et al.. (2020). 976TiP SPEARHEAD-2 trial design: A phase II pilot trial of ADP-A2M4 in combination with pembrolizumab in patients with recurrent or metastatic head and neck cancer. Annals of Oncology. 31. S685–S685. 2 indexed citations

11.

Zandberg, Dan P., Robert L. Ferris, Douglas Laux, et al.. (2020). 71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results. Annals of Oncology. 31. S1446–S1447. 23 indexed citations

12.

Das, Satya & Michael K. Gibson. (2018). Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma. PubMed. 14(2). 82–82. 2 indexed citations

13.

Bauml, Joshua, Tanguy Y. Seiwert, David G. Pfister, et al.. (2017). Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Journal of Clinical Oncology. 35(14). 1542–1549. 497 indexed citations breakdown →

14.

Haddad, Robert I., Tanguy Y. Seiwert, David G. Pfister, et al.. (2016). Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055. Annals of Oncology. 27. vi330–vi330. 11 indexed citations

15.

Argiris, Athanassios, Ryan P. Smith, Α. Kotsakis, et al.. (2011). Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Annals of Oncology. 22(11). 2482–2488. 12 indexed citations

16.

Zhang, Jie, et al.. (2010). The Platinum-Based Treatments for Advanced Non-small Cell Lung Cancer: Is Excision Repair Cross-Complementation Group 1 Low/Negative Expression Better Than Its High/Positive Expression? A Metaanalysis. CHEST Journal. 138(4). 778A–778A. 1 indexed citations

17.

Daniels, Jason, Michael K. Gibson, Li Xu, et al.. (2008). Gastrointestinal Tract Epithelial Changes Associated With Taxanes: Marker of Drug Toxicity Versus Effect. The American Journal of Surgical Pathology. 32(3). 473–477. 43 indexed citations

18.

Montgomery, Elizabeth A., Adam J. Mamelak, Michael K. Gibson, et al.. (2006). Overexpression of Claudin Proteins in Esophageal Adenocarcinoma and Its Precursor Lesions. Applied immunohistochemistry & molecular morphology. 14(1). 24–30. 47 indexed citations

19.

Gibson, Michael K. & Arlene A. Forastiere. (2004). Multidisciplinary approaches in the management of advanced head and neck tumors: state of the art. Current Opinion in Oncology. 16(3). 220–224. 59 indexed citations

20.

Gibson, Michael K., et al.. (1997). Interaction of p53 with the Human Rad51 Protein. Nucleic Acids Research. 25(19). 3868–3874. 178 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact